SLFN11 profoundly affects the response of colorectal cancer (CRC) to DNA-damaging chemotherapy drugs, including irinotecan and platinum (oxaliplatin, cisplatin), by participating in the DNA damage response pathway. Here, SLFN11 is linked to colorectal carcinoma.